Zacks: Brokerages Set $27.00 Target Price for Replimune Group Inc (REPL)

Shares of Replimune Group Inc (NASDAQ:REPL) have received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Analysts have set a twelve-month consensus price objective of $27.00 for the company and are predicting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also given Replimune Group an industry rank of 91 out of 255 based on the ratings given to its competitors.

A number of equities analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Replimune Group from a “hold” rating to a “sell” rating in a research note on Wednesday. BMO Capital Markets assumed coverage on shares of Replimune Group in a research note on Tuesday, August 14th. They issued an “outperform” rating and a $31.00 price objective for the company. Leerink Swann assumed coverage on shares of Replimune Group in a research report on Tuesday, August 14th. They set an “outperform” rating and a $25.00 target price for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Replimune Group in a research report on Tuesday, August 14th. They set an “overweight” rating and a $26.00 target price for the company.

Shares of REPL stock traded up $0.29 during mid-day trading on Wednesday, reaching $13.41. The company’s stock had a trading volume of 25,700 shares, compared to its average volume of 87,724. Replimune Group has a 1-year low of $10.52 and a 1-year high of $23.55.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, August 30th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($1.79). As a group, equities research analysts forecast that Replimune Group will post -1.18 earnings per share for the current year.

In other news, Director Joseph P. Slattery bought 6,667 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $100,005.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Fund Iv Gp L.P. Omega bought 266,667 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The shares were purchased at an average price of $15.00 per share, with a total value of $4,000,005.00. The disclosure for this purchase can be found here.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Further Reading: What is dollar cost averaging (DCA)?

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply